BTX 1503 acne Phase 2 clinical trial currently underway across US and Australian sites with data expected in mid-CY2019
Key highlights
· BTX 1503 acne Phase 2 clinical trial currently underway across US and Australian sites with data expected in mid-CY2019
· Positive patient testimony from one of the first patients enrolled in the BTX 1503 acne Phase 2 clinical trial
Philadelphia PA and Sydney Australia, 12 September 2018 -- Medical dermatology company Botanix Pharmaceuticals Limited (ASX:BOT, “Botanix” or the “Company”), is pleased to advise that following the recent commencement of the BTX 1503 acne Phase 2 clinical trial, one of the first patients enrolled into the clinical trial has demonstrated promising early results and provided a positive testimony.
To watch the 7News feature, please click here
To read the ASX announcement, please click here
Have you seen our earlier videos?
Click here to visit our new YouTube page
Click here to watch an introduction to Botanix Pharmaceuticals
Click here to watch the BTX 1204 Presentation
Click here to watch an interview with CMO, Dr Stephane Levy
For more information, please visit www.botanixpharma.com or follow us on Twitter @BotanixPharma
General Enquiries
Matt Callahan
Botanix Pharmaceuticals
Executive Director
P: +1 215 767 4184
E: mcallahan@botanixpharma.com
Investor Enquiries
Joel Seah
Vesparum Capital
P: +61 3 8582 4800
E: botanixpharma@vesparum.com
Media Enquiries
Julia Maguire
The Capital Network
P: +61 419 815 386
E: julia@thecapitalnetwork.com.au
